Abstract
Background Vaccines and monoclonal antibodies to protect the very young infant against respiratory syncytial virus (RSV)-associated illness are effective for limited time periods. We aimed to estimate age-specific burden to guide implementation strategies and cost effectiveness analyses.
Methods We combined case-based surveillance and ecological data to generate a national estimate of the burden of RSV-associated acute respiratory illness (ARI) and severe acute respiratory illness (SARI) in South African children aged <5 years (2011-2016), including adjustment for attributable fraction. We estimated the RSV burden by month of life in the <1-year age group, by 3-month intervals until 2 years and then 12 monthly intervals to <5 years for medically and non-medically attended illness.
Results We estimated a mean annual total (medically and non-medically attended) of 264,112 (95% Confidence interval (CI) 134,357-437,187) cases of RSV-associated ARI and 96,220 (95% CI 66,470-132,844) cases of RSV-associated SARI (4.7% and 1.7% of the population aged <5 years, respectively). RSV-associated ARI incidence was highest in 2 month-old infants (18,361/100,000 population, 95% CI 9,336-28,466). The highest incidence of RSV-associated SARI was in the <1-month age group 14,674/100,000 (95% CI 11,175-19,645). RSV-associated deaths were highest in the first and second month of life (8.7 deaths/100 000 (95% CI 6.3-11.2) and 8.7 deaths/100 000 (95% CI 6.4-11.4), respectively).
Conclusion Due to the high burden of RSV-associated illness, specifically SARI cases in young infants, maternal vaccination and monoclonal antibody products delivered at birth could prevent significant RSV-associated disease burden.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The data collection for this study was funded by a grant to the institution from the Centers for Disease Control and Prevention Atlanta, Georgia. The analysis and manuscript development was funded by a grant to the institution from PATH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of the Witwatersrand's Human Research Ethics committee gave approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
